GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) » Definitions » LT-Debt-to-Total-Asset

Oxford Cannabinoid Technologies Holdings (LSE:OCTP) LT-Debt-to-Total-Asset : 0.00 (As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oxford Cannabinoid Technologies Holdings's long-term debt to total assests ratio for the quarter that ended in Oct. 2023 was 0.00.

Oxford Cannabinoid Technologies Holdings's long-term debt to total assets ratio stayed the same from Oct. 2022 (0.00) to Oct. 2023 (0.00).


Oxford Cannabinoid Technologies Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings LT-Debt-to-Total-Asset Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
LT-Debt-to-Total-Asset
- - 0.04 - -

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only - - - - -

Oxford Cannabinoid Technologies Holdings LT-Debt-to-Total-Asset Calculation

Oxford Cannabinoid Technologies Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2023 is calculated as

LT Debt to Total Assets (A: Apr. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Apr. 2023 )/Total Assets (A: Apr. 2023 )
=0/4.496
=

Oxford Cannabinoid Technologies Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2023 is calculated as

LT Debt to Total Assets (Q: Oct. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Oct. 2023 )/Total Assets (Q: Oct. 2023 )
=0/2.79
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Cannabinoid Technologies Holdings  (LSE:OCTP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Oxford Cannabinoid Technologies Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings Business Description

Traded in Other Exchanges
N/A
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings Headlines

No Headlines